IFM Investors Pty Ltd Purchases 4,225 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

IFM Investors Pty Ltd grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,800 shares of the medical equipment provider's stock after purchasing an additional 4,225 shares during the period. IFM Investors Pty Ltd's holdings in Zimmer Biomet were worth $4,512,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Garde Capital Inc. purchased a new stake in shares of Zimmer Biomet in the first quarter valued at about $29,000. Menard Financial Group LLC purchased a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Washington Trust Advisors Inc. purchased a new stake in Zimmer Biomet during the first quarter worth about $30,000. Accredited Wealth Management LLC purchased a new stake in Zimmer Biomet during the fourth quarter worth about $36,000. Finally, OFI Invest Asset Management purchased a new stake in Zimmer Biomet during the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.39% of the company's stock.

Zimmer Biomet Price Performance

ZBH stock traded down $0.05 during midday trading on Thursday, reaching $95.15. The company had a trading volume of 2,345,927 shares, compared to its average volume of 1,819,283. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71. The company has a market capitalization of $18.83 billion, a P/E ratio of 21.05, a P/E/G ratio of 2.16 and a beta of 0.71. The firm has a 50-day moving average price of $93.51 and a 200-day moving average price of $101.52.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The business had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same quarter in the previous year, the company earned $1.94 EPS. The business's quarterly revenue was up 1.1% compared to the same quarter last year. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.01%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Analysts Set New Price Targets

ZBH has been the subject of a number of research analyst reports. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Wells Fargo & Company decreased their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Raymond James Financial decreased their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Finally, Morgan Stanley cut their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $110.56.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.